A novel G-protein-coupled receptor-signaling platform and its targeted translation in human disease

Samar Abdulkhalek1
Michael Hrynyk2
Myron R Szewczuk1
1Departments of Biomedical and Molecular Sciences, 2Chemical Engineering, Queen’s University, Kingston, ON, Canada

Abstract: Molecular-targeted G-protein-coupled receptor (GPCR) signaling in human disease has become an important area of scientific and medical research. The interactions between GPCRs with their large number of different G-protein subunits and the large number of glycosylated receptors involved in human diseases are quite diverse. One GPCR is capable of interacting with more than one G protein to initiate multifunctional signaling. However, the activation of a number of GPCRs does not always lead to a direct effect alone on a particular signaling pathway, but rather to an amplification of the response produced by a separate circumstantial signal within the cell. This cross talk among different GPCR transduction signals is a focus of intense research. In this review, evidence exposing the invisible link connecting ligand-binding and receptor activation to a novel GPCR-signaling platform will be reviewed in relation to human disease.

Keywords: G-protein-coupled receptors, toll-like receptors, receptor tyrosine kinase, glycosylation, Neu1 sialidase, matrix metalloproteinase

Introduction

G-protein-coupled receptors (GPCRs) comprise the largest family of cell-surface signal-transduction molecules in mammalian cells. A vast array of stimuli is capable of eliciting conformational changes in these receptors, resulting in the activation of intracellular heterotrimeric G proteins.1 They are activated by many ligands, both internal within the body, such as hormones and neurotransmitters, and external light, odorants, and others. GPCRs undergo conformational changes upon ligand interaction, which results in the intermediate coupling and activation of guanine triphosphate (GTP)-binding G proteins (guanine nucleotide regulatory proteins, which are composed of α-, β- and γ-subunits), leading to the exchange of GDP for GTP on the Gα subunit. This interactive process(es) of G proteins results in the dissociation of the GPCR receptor from the G proteins as well as the GαATP subunit from the Gβγ subunit. Both subunits are able to interact with various effector enzymes, leading to complex G-protein-mediated signaling pathway(s).1–8

These heterotrimeric G proteins are classically categorized by their α subunits, and can be grouped into four major families: Gs, Gi/o, Gq/11, and G12/13.9 However, alternate pathways of GPCR-mediated signaling that are independent of G-protein interaction and/or activation of secondary effector molecules have been increasingly reported. These alternate GPCR-signaling responses are the result of cross talk between various intracellular signaling networks.1 For a number of these GPCRs
to date, their ligands are still unknown, and their receptors are classified as GPCR orphans.10

Studies have shown that glycosylation of secreted and cell membrane-bound receptors is an important requirement for their transport and function. For example, partial glycosylation is an important requirement for at least the processing and/or ligand-binding activity of insulin receptor,11 epidermal growth factor receptor,12,13 nicotinic acetylcholine receptor,14 and members of the G-protein-coupled class of receptors, such as the vasoactive intestinal peptide receptor,14 somatostatin receptor,15 and β-adrenergic receptor.16,17 For nerve growth factor (NGF) tropomyosin receptor kinase A (TrkA) receptors, glycosylation is required to localize the receptor to the cell surface, where glycosylation is suggested to prevent receptor autophosphorylation.18 In addition, the treatment of TrkA-expressing cells by exogenous Trypanosoma cruzi trans-sialidase or α2,3-neuraminidase (Streptococcus pneumoniae) leads to TrkA activation sufficient to promote cell differentiation (neurite outgrowth)19 and neuroprotection against oxidative stress, serum/glucose deprivation, and hypoxia-induced neurite retraction.20 Based on these latter results, it was proposed that a specific α-2,3-sialyl residue linked to β-galactosyl sugars of TrkA are rapidly targeted and hydrolyzed by a membrane sialidase(s) induced by NGF binding to TrkA.21

It is well known that glycoproteins and glycolipids expressed at the cell surface of eukaryotic cells can be modified to varying degrees by the addition of sialic acids (N-acetyneuraminic acid or other N- and O-substituted neuraminic acids).22 Sialic acid residues in specific linkages are known to control the chemical and biological properties of cell surfaces23 and the exposure of epitopes.24 Sialic acids play important roles as molecular determinants of specific biological processes such as cell–cell interactions,25–28 T- and B-cell activation, hematopoietic cell differentiation,29 tumorigenicity, and metastatic behavior of malignant cells29 and the control of Fas-mediated apoptosis.22 Although there is extensive literature on the role of sialic acid in protein structure (see reviews10–13), there are very few examples of a role for sugars in signal transduction. One is the addition of a single sugar to the Notch receptor, which becomes substituted and eventually obtains sialic acids on the terminus of the chain. Notch is a large cell-surface receptor known to be an essential player in a wide variety of developmental cascades. This single O-linked carbohydrate modification is essential for Notch signaling.33 The other examples are the role of glycosylation in TrkA activation by NGF21 and in Toll-like receptor (TLR-2, -3, and -4) activation by their respective TLR ligands.34,35

**Novel GPCR-signaling platform for tyrosine kinase receptors**

For TrkA receptors, we have reported that there is a mammalian neuraminidase-1 (Neu1 sialidase) and matrix metalloproteinase-9 (MMP-9) cross talk on the cell surface, which was an essential requirement for regulating NGF activation of TrkA receptors.36 It discloses a novel receptor-signaling paradigm involving NGF-induced GPCR-signaling process via Gαi proteins and MMP-9 activation in inducing Neu1 sialidase, all of which form a tripartite complex with TrkA at the ectodomain on the cell surface (Figure 1). MMP-9, or gelatinase B, is one of the largest and most complex member of the MMP family of at least 28 members.37 MMP-9 can bind to gelatin, collagens type I, IV, and V, and other substrates.38,39 It is the elastin-degrading activity of MMP-940,41 that fits well within this novel signaling paradigm of TrkA activation. This process involves the elastin-binding protein (EBP) as part of the molecular multi-enzymatic complex that contains β-galactosidase/Neu1 and protective protein cathepsin A. Direct removal of EBP from the complex by activated MMP-9 is proposed to activate Neu1. Alternatively, binding of elastin fragments to EBP may induce activation of Neu1 by EBP dissociation, subsequently allowing activated Neu1 to desialylate the α-2,3 sialyl residues of TrkA and to facilitate receptor association and activation.36

It is known that Neu1 sialidase is associated with a serine carboxypeptidase (protective protein cathepsin A), β-galactosidase and N-acetylgalactosamine-6-sulfate sulfatase in the lysosome.42 Cathepsin A is required for normal Neu1 enzymatic activity43 and is sorted to the plasma membrane of differentiating monocytes similar to Neu1.42 Cell-surface Neu1/cathepsin A can also associate with EBP, forming the elastin receptor complex, where the catalytic activity of Neu1 facilitates elastic fiber assembly44 and signal transduction.45 Neu1 can be detected not only within the lysosome matrix but also in the plasma membrane under conditions of cell stimulation.46 In another study, Neu1 was found to negatively regulate lysosomal exocytosis in hematopoietic cells where it processes the sialic acids on the lysosomal-associated membrane protein 1.47 On the cell surface, we have reported an unprecedented role for Neu1.36 It forms a complex with TrkA receptors, as depicted in Figure 1, but also forms a complex with TLR2, -3, and -4 receptors on the cell surface, which has not been previously observed.34,35
There are three other mammalian sialidases that have been classified according to their subcellular localization. They are cytosolic Neu2, plasma membrane-bound Neu3, and Neu4. The cytosolic Neu2 sialidase normally shows lower expression levels among the mammalian sialidases, except for high Neu2 levels in skeletal muscle, the liver, and the thymus, and low levels in the brain. Membrane Neu3 sialidase appears to specifically hydrolyze monosialotetrahexosylgangliosides, and is referred to as plasma membrane ganglioside sialidase. A new Neu4 sialidase was cloned from murine brain and has similarities to Neu3. There is evidence for a human Neu4 sialidase localized to the mitochondrial and the lysosomal lumen. However, there is a paucity of information for a function role of Neu4 sialidase. We have recently reported that thymoquinone, an extract from black seed oil, induces Neu4 activation. In Figure 2, activated Neu4 in alliance with MMP-9 and GPCR signaling via pertussis toxin-sensitive Gαi proteins was found to play an important role in regulating TLRs.

Stomatos and colleagues have shown that Neu1 on the cell surface is tightly associated with a subunit of cathepsin A, and the resulting complex influences cell-surface sialic acid in activated cells in the production of interferon (IFN)-γ. At the genetic level, Neu1-deficient mice produce markedly less immunoglobulin (Ig)E and IgG, antibodies following immunization with protein antigens, which may be the result of their failure to make interleukin (IL)-4 cytokine. Using similar Neu1-deficient mice, we have found that serum proinflammatory cytokines are induced in wild-type (WT) and Neu1-deficient mice in response to lipopolysaccharide (LPS) after 5 hours of treatment when compared to basal serum levels. However, the Neu1-deficient mice in response to LPS produced a significant reduction in complement C5 component fragment (C5a), granulocyte colony-stimulating factor, IL-1 receptor antagonist, IL-6, cytokine-induced neutrophil chemoattractant, and macrophage inflammatory protein-2 cytokines compared to the WT mice. Using an IL-6 enzyme-linked immunosorbent assay, serum IL-6 was significantly reduced in LPS-treated Neu1-deficient mice compared to the WT cohort. In addition, in vitro treatment of human monocytic THP-1 with oseltamivir phosphate (Tamiflu) dose-dependently inhibited IL-6 and tumor necrosis factor (TNF)-α production in response to LPS. Oseltamivir phosphate also significantly inhibited the production of nitric oxide (NO) in DC2.4 dendritic cells in response to LPS or killed Mycobacterium butyricum stimulation. These results are consistent with other reports indicating that oseltamivir reduces a synergy between influenza and IFN-γ in NO synthesis in RAW 264.7 macrophages dose-dependently. It is noteworthy that Tamiflu is the ethyl ester prodrug of the anti-influenza drug oseltamivir carboxylate, which is converted to this biologically active form in vivo.
by the hydrolytic metabolite oseltamivir carboxylate form,68 we have actually observed the opposite effect in our live-cell assay system.35,69 To further elucidate the inhibitory capacity of Tamiflu and its hydrolytic metabolite oseltamivir carboxylate, the 50% inhibitory concentration (IC$_{50}$) of each compound was determined by plotting the decrease in sialidase activity against the log of the agent concentration. Tamiflu was found to have an IC$_{50}$ of 1.175 µM compared to an IC$_{50}$ of 1015 µM for oseltamivir carboxylate.35 These data clearly illustrated that Tamiflu is 1000-fold more potent than its hydrolytic metabolite in inhibiting the sialidase activity associated with TLR ligand-treated live BMC-2 macrophage cells. Together, these results clearly indicated that Tamiflu is a potent inhibitor of the sialidase associated with TLR ligand-treated live macrophage cells.35

To further confirm Neu1 involvement in LPS-induced NO production and proinflammatory cytokines, primary bone marrow (BM) macrophage cells from Neu1-deficient mice were found to exhibit a significant reduction in endotoxin LPS-induced NO production in comparison to a WT cohort. Here, it was proposed that TLR ligand-induced proinflammatory IL-6, TNF-α cytokines, and NO production are partially dependent on Neu1 sialidase activity.35

### A Novel GPCR-Signaling Platform for Toll-like Receptors

Evidence for the interaction between TLRs and GPCRs came initially from the effect of TLRs on GPCR activity. Activation of TLRs has been shown to regulate GPCR responsiveness by modulating the expression of GPCR kinases (GRKs), arrestins (ARRs), and regulators of G-protein-signaling (RGS) proteins.70,71 GRKs phosphorylate and ARRs bind to GPCRs to inhibit G-protein-dependent signaling. Various RGS proteins that act specifically on different Gα subunits and thus stimulate specific pathways are induced by specific TLRs.70 For example, the RGS proteins are known to control the rate of GTP hydrolysis on the Gα subunit of heterotrimeric G proteins. Together with GRKs and ARRs, they regulate the duration of signaling downstream of GPCRs. Indeed, the RGS family of proteins, comprising 30 members, is diverse, ranging in size from 17 kDa to 160 kDa and displaying widely variable and regulated expression patterns.72 Most RGS proteins have GTPase
activity specific for the \( \alpha_q \) and \( \alpha_i \) subfamilies of the \( \alpha \)-subunits. Some RGS proteins can also function essentially as effector antagonists through competitive inhibition of effector–\( \alpha \)-protein interactions. According to Lattin et al., the mRNA levels for \( RGS1, -2, -10, -18 \), and -19 are highly expressed in macrophage cells or are strongly upregulated by the TLR4 receptor ligand LPS.\(^7\) It is unclear whether any of the RGS family of proteins form a complex with TLR receptors. However, there is evidence to indicate that RGS19 and GIPC (\( \alpha \)-interacting protein [GAIP]) interacts specifically with the PDZ-containing protein, GAIP-interacting protein, C-terminus) heterodimer forms a complex with insulin growth factor receptor 1 (IGF-1) to consolidate IGF-1 signaling to the mitogen-activated protein kinase (MAPK) activation.\(^7\) The RGS19/GAIC heterodimer has been shown to form a complex with the NGF receptor TrkA.\(^7\) It remains unclear how this complex affects signaling via these receptors.

Other studies have demonstrated that (1) proteinase-activated receptor 2 (PAR\(_2\)) GPCR and TLR4 were physically associated, and coexpression of PDZ4 and PAR\(_2\) enhanced the protein factor kappa light-chain enhancer of activated B cells (NF-\( \kappa \)B) signaling,\(^7\) and (2) the TLR4-associated CD14 protein communoprecipitated with G-protein subunits,\(^7\) and CD14 associated with TLR4 in lipid membrane rafts.\(^7\) The physical association of TLRs with the GPCRs provides firstly the mechanism by which GPCRs can be activated upon TLR-ligand binding. The physical GPCR-TLR association could also facilitate the transmission of the signal from the GPCR to the Neu1/TLR complex and consequently to the TLRs.\(^7\) Taken together, these studies strongly suggest that TLRs and GPCRs are found associated, physically and functionally, in cellular functioning. GPCR signaling appears to influence TLR signaling early on, perhaps at the receptor level. In macrophages and dendritic cells, for example, GPCRs regulate diverse cell functions, including cell–cell interactions, survival, chemotaxis, and activation, involving cross talk between GPCR- and TLR-signaling pathways.\(^7\)\(^,\)\(^7\)\(^9\)

The involvement of heterotrimeric \( \alpha \)-proteins in ligand-mediated TLR function has been reported. Solomon et al.\(^7\) have demonstrated that CD14 (an integral component of the Gram-negative bacterial LPS-receptor complex, along with TLR4 and MD2) was associated with \( \alpha_i \) (inhibitory class) and \( \alpha_q \) (olfactory class) \( \alpha \) subunits of G proteins. The report also indicated that heterotrimeric G proteins have a specific regulatory function in CD14-mediated LPS-induced MAPK activation and cytokine production in normal human monocytes. When human monocyte THP-1 cells were pretreated with pertussis toxin which specifically inhibits \( \alpha_i \)-receptor coupling, there was a significant decrease in LPS-induced activation of c-Jun N-terminal kinase and p38 kinase, and the production of TNF-\( \alpha \).\(^8\) In addition, Fan et al.\(^1\) have shown that \( \alpha_i \) protein differentially regulates LPS-mediated signaling through TLR4, and Gram-positive Staphylococcus aureus-mediated signaling through TLR2. Using the knockout mouse models \( \alpha_q^{\beta \alpha} \) and \( \alpha_i^{\beta \alpha} \), the study showed significantly decreased TLR ligand-mediated TNF-\( \alpha \) and IL-10 production in peritoneal macrophages of the knockout mice compared to WT mice. Surprisingly, in splenocytes from the same knockouts, significant increases in TNF-\( \alpha \) and IFN-\( \gamma \) production in response to TLR ligands were detected. These data suggest a regulatory role for \( \alpha_i \) proteins in TLR signaling that is potentially dependent on the cellular phenotype.\(^8\) In the murine RAW 264.7 macrophage cell line, and primary murine macrophages, G-protein dysregulation by wasp venom-derived peptide mastoparan caused a significant inhibition in LPS-induced TLR4- but not TLR2-mediated gene expression.\(^8\) It is well known that mastoparan directly activates \( \alpha_i \) (inhibitory class) and \( \alpha_q \) (olfactory class) \( \alpha \) subunits of G proteins. However, the mastoparan-induced biological responses are not always explained by this mechanism. For instance, mastoparan was shown to change the localization of \( \alpha_q^{\beta \alpha} \) and GB together with cholesterol from lipid rafts to nonraft fractions or to the cytosol.\(^8\) These changes were inhibited by ganglioside mixtures, suggesting that mastoparan interacts with gangliosides in lipid rafts. In fact, ganglioside mixtures and neuraminidase, but not sialic acid, attenuated the inhibitory effect of mastoparan on phosphoinositide hydrolysis. These results suggest that mastoparan initially binds to gangliosides in lipid rafts and then inhibits phosphoinositide hydrolysis by changing the localization of \( \alpha_q^{\beta \alpha} \) and GB in lipid rafts.

The mammalian TLRs are sensor receptors that recognize pathogen-associated molecular patterns. Not only are TLRs important sensors of microbial infections for innate immune cells, they also play important roles in the pathophysiology of inflammatory and autoimmune diseases. The intensity and duration of TLR responses with these diseases must be tightly controlled. Although the signaling pathways of TLR sensors are well characterized, the parameters controlling interactions between TLRs and their ligands have remained poorly defined until now.

For the majority of TLR receptors, dimerization is a prerequisite to facilitate myeloid differentiation primary response gene-88 (MyD88)–TLR complex formation and subsequent cellular signaling to activate NF-\( \kappa \)B.
previously reported that Neu1 is an important intermediate in the initial process of TLR ligand-induced receptor activation and subsequent cell function. The data indicated an initial rapid activation of Neu1 activity that was induced by ligand binding to the receptor. Central to this process is that only Neu1 forms a complex with TLR2, -3 or -4 receptors in naïve TLR-expressing cells or primary macrophage cells. However, an unexpected membrane-signaling paradigm initiated by TLR ligands binding to TLR receptors was recently uncovered. The results indicated that the interaction of TLR ligands with their receptors initiates the potentiation of GPCR-signaling via membrane $\alpha$-subunit proteins and MMP-9 activation to induce Neu1 activity. Neu1 together with GPCR-signaling $\alpha$-subunit proteins and MMP-9 form a complex with TLRs on the cell surface of TLR-expressing cells. This tripartite alliance makes Neu1 readily available to be induced by TLR ligands binding to their receptors. It is well known that agonist-bound GPCRs have been shown to activate numerous MMPs, including MMP-3, MMP-2, and -9, as well as members of the A disintegrin and metalloproteinase (ADAM) family of metalloproteases: ADAM10, ADAM15, and ADAM17. This membrane-signaling paradigm suggests a Neu1 and MMP-9 cross talk in alliance with GPCR signaling through $\alpha$ subunit proteins and TLRs on the cell surface to mediate receptor activation. Our other reports support a receptor glycosylation model in corroborating the importance of activated Neu1 hydrolysis of sialyl $\alpha$-2,3-linked $\beta$-galactosyl residues of TLR in the initial stages of ligand-induced receptor activation. This desialylation process is proposed to remove steric hindrance to TLR dimerization, MyD88/TLR complex recruitment, NF-κB activation, and proinflammatory cytokine response.

Conversely, it is well known that GPCR agonists can induce transactivation of TLR receptors independently of TLR ligands, but the mechanism(s) behind GPCR agonist-induced transactivation of TLRs in the absence of TLR ligands is unknown. We have recently reported a molecular organizational GPCR-signaling platform that potentiates Neu1 and MMP-9 cross talk at the ectodomain of TLRs on the cell surface. This GPCR-signaling platform is proposed to be the cellular signaling mechanism for the transactivation of TLR receptors by GPCR ligands. It also predicts that TLRs are in alliance with a functional GPCR-signaling complex. The data show that GPCR agonists such as bombesin, lysosphatidic acid (LPA), cholesterol, angiotensin-1 and -2, and bradykinin binding to their respective GPCR receptors can induce Neu1 activity within 1 minute, and that this activity is blocked by $\alpha$-sensitive pertussis toxin, neuraminidase inhibitor Tamiflu, broad-range MMP inhibitors galardin and piperazine, anti-Neu1 and anti-MMP9 antibodies, and siRNA knockdown of MMP-9. The rapidity of the GPCR agonist-induced Neu1 activity suggests that glycosylated receptors like TLRs form a functional GPCR-signaling complex. In support of this hypothesis, the bombesin-related neuromedin-B receptor was found to form a complex tethered to TLR4 receptors on the cell surface in BMA (murine bone marrow macrophages immortalized with a retrovirus carrying oncogenes myc and raf) macrophage cells. These data are consistent with reports describing cross talk between GPCR- and TLR-signaling pathways. In addition, we have shown that other GPCR-specific agonists binding to their respective receptors induce sialidase activity in live macrophage cells. For example, LPA is a lysosphospholipid whose functions are mediated by at least four GPCRs. These receptors couple to multiple G proteins, particularly $G_{12/13}$, $G_{i}$, and $G_{q}$ and possibly $G_{16}$. Cholesterol has been reported to have a modulatory role in the function of a number of GPCRs. According to Paila and Chattopadhyay, membrane cholesterol could influence the structure and function of GPCRs (1) through a direct/specific interaction with GPCRs, (2) through an indirect way by altering membrane physical properties in which the receptor is embedded, or (3) due to a combination of both. Indeed, cholesterol-binding sites were shown to have inherent characteristic features of serotonin (1A) receptor which is a GPCR that is coupled to $G_{i}$ and mediates inhibitory neurotransmission. For the angiotensins, they mediate their actions via several specific AT$_{1}$, AT$_{2}$, and MAS receptors. The angiotensin receptor is activated by the vasoconstricting peptide AT$_{2}$. The activated receptor in turn couples to $G_{q/11}$ and thus activates phospholipase C and increases the cytosolic Ca$^{2+}$ concentrations. Although AT$_{1}$ has no biological effects, it was found to induce sialidase activity in our live-cell assay, which may provide an uncharacterized activity for this compound. For bombesin, all the receptor subtypes identified to date couple via $G_{q/11}$, to the phospholipase C-signaling pathway. For thrombin, we did not observe any sialidase activity when the cells were treated with it. The thrombin receptor is known to activate phosphoinositide metabolism via a pertussis toxin-insensitive G protein. It also inhibits adenylyl cyclase via a pertussis toxin-sensitive G protein. There are three known thrombin protease-activated receptors – termed PAR$_{1}$, PAR$_{2}$, and PAR$_{4}$ – but their method of activation is known to be unique. Thrombin is a serine protease that binds to and cleaves the extracellular N-terminal domain of the receptor. A tethered ligand corresponding to the new N-terminus, SFLLRN, is unmasked, and it binds to the second extracellular loop of the
receptor, thus activating the receptor. Bradykinin, on the other hand, binds to the ubiquitous and constitutively expressed B₂ receptors which are members of the rhodopsin family of G-protein-coupled receptors. Through Gαq-mediated signaling, B₂ receptors stimulate phospholipase C to increase phosphoinositide hydrolysis and intracellular free Ca²⁺. B₂ signaling through Gαq also inhibits adenylate cyclase to stimulate the MAPK pathway.²

Collectively, the above GPCR agonists that induce Neu1 sialidase activity commonly use the G₁₂/₁₃, Gαi, Gq, and Gq/₁₁ signaling proteins.²⁸ Others have shown that sphingosine-1 phosphate (S1P) and S1P₃ expressions are induced by LPS in human gingival epithelial cells (HGEC), and that these elevated expressions enhanced the influence of S1P in its cooperation with TLR4 to increase cytokine production.⁹³ The relationship between GPCR signaling and TLR has also been shown for (1) CC chemokine ligand 2 synergizing with the nonchemokine G-protein-coupled receptor ligand N-formylmethionyl leucyl-phenylalanine in monocyte chemotaxis,⁹⁴ (2) complement C₁q expression in macrophages requiring beta-arrestin 2 where beta-arrestins (ARRB1 and ARRB2) regulate GPCR-dependent and independent signaling pathways,⁹⁵ (3) leukotriene B₄ receptor BTL1 by reducing suppressor of cytokine signaling proteins 1 inhibition of MyD88 expression in mouse macrophages,⁹⁶ and (4) GPCR-derived cyclic adenosine monophosphate signaling in influencing TLR responses in primary macrophages through peptide disruptors of A-kinase anchoring protein 10 involving prostaglandin E₂.⁹⁷ Using MyD88 homodimerization inhibitor peptide, we have reported that GPCR bombesin activation of NF-κB in macrophage cells is initially mediated via a novel molecular GPCR organizational signaling platform in concert

---

**Figure 3** GPCR agonists activate GPCR tethered to TLR4 and MMP9 to induce Neu1 sialidase in macrophage cells. **Notes:** Reciprocally, endotoxin lipopolysaccharide (LPS)-binding MMP9 induces GPCR tethered to TLR4 and MMP9.⁹⁴ GPCR agonists or TLR ligands involve the activation of GPCR-signaling via pertussis toxin-sensitive Gα-proteins to induce MMP-9. Activated MMP-9 is proposed to remove elastin-binding protein (EBP) to activate Neu1 in complex with protective protein cathepsin A (PPCA). Activated Neu1 hydrolyzes α₂,3-sialic acid residues at the ectodomain of the TLR4 receptor to facilitate receptor association, MyD88 recruitment, and subsequent downstream NF-κB activation.

**Abbreviations:** TLR4, Toll-like receptor 4; Neu, neuraminidase; PPCA, protective protein cathepsin A; GTP, guanine triphosphate; EBP, elastin-binding protein; MyD88, myeloid differentiation primary response gene 88; MAL, MyD88-adaptor-like; TRAM, Toll/IL-1 receptor (TIR) domain-containing adaptor-inducing interferon-β (TRIF)-related adaptor molecule; TRIF, TIR-domain-containing adapter-inducing interferon-β (TRIF)-related adaptor molecule; TRIF, TIR-domain-containing adapter-inducing interferon-β (TRIF)-related adaptor molecule; TRIF, TIR-domain-containing adapter-inducing interferon-β (TRIF)-related adaptor molecule; TRAF6, tumor necrosis factor-receptor associated factor 6; Lys63, lysine 63-linked polyubiquitin chains; A20, ubiquitin-modifying enzyme by removing ubiquitin moieties from the signaling molecule TRAF6; TAB1, transforming growth factor beta (TGF/β)-activated kinase 1; TAB1, TGF-beta activated kinase 1/mitogen activating protein (MAP) kinase kinase kinase 7 (MAP3K7) binding protein 1; Ubc13, ubiquitin conjugating enzyme 13; Uev1A, an ubiquitin conjugating enzyme variant which is required for Ubc13 catalyzed poly-ubiquitination of target proteins through Lys63-linked chains; NEMO/iKKγ, nuclear factor-κB (NFκB) essential modulator/inhibitor of NFκB (iκB) protein kinase γ; IKKγ; iκB kinase γ; iκB, nuclear factor of κ light polypeptide gene enhancer in B-cell inhibitor; NFκB, nuclear factor κ-light-chain enhancer of activated B cells.
with the TLR receptor, as previously proposed by us, but the subsequent bombesin-induced NF-κB is actually mediated through the activation of TLR (see Figure 3).

**Novel GPCR-signaling platform and its targeted translation to human disease**

GPCRs have long been implicated in the transactivation of receptor tyrosine kinases (RTKs) in the absence of added growth factor, particularly for the receptors that bind epidermal growth factor, platelet-derived growth factor, fibroblast growth factor, and neurotrophins such as nerve growth factor. In a review by Delcourt and colleagues, the authors provide an eloquent attempt to explain the molecular mechanisms involved in this novel cross-communication between GPCRs and RTKs. Reciprocally, growth factors binding to RTKs also utilize GPCR-signaling molecules to initiate the molecular organizational signaling-platform of a novel Neu1 and MMP-9 cross talk in alliance with RTK on the cell surface. This novel GPCR-signaling platform was identified to be critically essential for neurotrophin NGF-induced receptor tyrosine kinase TrkA and TrkB activation and cellular signaling (see Figure 1). These findings have revealed a novel concept in which GPCR activation is critically essential for growth-factor activation of RTK by way of a mechanism that involves the formation of a functional signaling complex between the GPCR and RTK. The exact same signaling platform is utilized by Toll-like sensor receptors binding pathogen-associated molecular patterns to activate TLR cellular responses (Figures 2 and 3). The mechanism(s) of TLR transactivation by GPCR agonists has not been defined until now (see Figure 3). However, GPCR transactivation by RTK ligands or by TLR pathogen-associated molecular patterns has been established for a few GPCR-RTK (see Table 1) or GPCR-TLR pairs. Indeed, there is a need to investigate other partners.

In the context of GPCR-RTK pairs, whether the GPCRs known to promote proliferation signals such as thrombin, angiotensin 2, and endothelin receptors can be transactivated by RTK ligands, or reciprocally RTK transactivation by GPCR agonists remains to be determined. The receptor-signaling paradigm in Figure 1 predicts that RTK receptors are in alliance with a functional GPCR-signaling complex. The data in this and our other reports show that ligand binding to respective receptors induces Neu1 sialidase activity within a minute, and that this activity is completely blocked by Gαi-sensitive pertussis toxin. The rapidity of the ligand-induced Neu1 sialidase activity mediated by the ligand-bound receptor suggests that glycosylated receptors like NGF TrkA, BDNF TrkB, and TLRs form a functional signaling complex with Gαi proteins of GPCRs. In support of this hypothesis, GPCR agonists bombesin, LPA, cholesterol, angiotensin-1 and -2, but not thrombin, induce sialidase activity within a minute, and this activity was blocked by Gαi-sensitive pertussis toxin and MMP inhibitors galardin and piperazine. It is noteworthy that the GPCR agonists can induce sialidase activity in the live-cell assay but the GPCR-mediated effects were not observed in RTK-deficient cells such as NIH-3T3 cells (data unreported). These results suggest that GPCR agonists activate sialidase activity only when Neu1 and a functional GPCR are tethered to an RTK receptor. To confirm this hypothesis, we recently reported that the GPCR ligand bombesin induced Neu1 activity within a minute and subsequently activated NF-κB in macrophage cells. We also questioned whether the bombesin-like receptor neuromedin B (NMBR) forms a complex with TLR4. Coimmunoprecipitation experiments using cell lysates from BMA macrophage cells showed that NMBR is tethered to TLR4 receptors in naïve and LPS-treated cells. The data validated the predicted alliance between TLR4 and NMBR in naïve macrophage cells. In another report, we have shown that MMP-9 is also tethered

<table>
<thead>
<tr>
<th>RTK ligand</th>
<th>Transactivated GPCR</th>
<th>Molecular mechanism</th>
<th>Functions</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-I</td>
<td>CXCR4</td>
<td>Physical interaction</td>
<td>Cell migration</td>
<td>99</td>
</tr>
<tr>
<td>IGF-I</td>
<td>CCR5</td>
<td>Ligand synthesis</td>
<td>Cell migration</td>
<td>100</td>
</tr>
<tr>
<td>IGF-I</td>
<td>PAC1</td>
<td>Physical interaction and phosphorylation</td>
<td>Protection against apoptosis</td>
<td>101</td>
</tr>
<tr>
<td>IGF-I</td>
<td>SIP1</td>
<td>Ligand synthesis</td>
<td>Cell migration</td>
<td>102</td>
</tr>
<tr>
<td>Insulin</td>
<td>β2 adrenoceptor</td>
<td>Phosphorylation</td>
<td>Unknown</td>
<td>103</td>
</tr>
<tr>
<td>PDGF</td>
<td>SIP1</td>
<td>Ligand synthesis and physical interaction</td>
<td>Cell motility and migration</td>
<td>104–111</td>
</tr>
<tr>
<td>NGF</td>
<td>SIP1</td>
<td>Ligand synthesis</td>
<td>Neurite outgrowth</td>
<td>112</td>
</tr>
<tr>
<td>NGF</td>
<td>LPA1</td>
<td>Physical interaction</td>
<td>Neurite outgrowth</td>
<td>113,114</td>
</tr>
</tbody>
</table>


*Abbreviations: RTK, receptor tyrosine kinase; GPCR, G-protein-coupled receptor; IGF-1, insulin-like growth factor 1; CXCR4, CXC chemokine receptor type 4; CCR5, CC chemokine receptor 5; PAC1, neuropeptide GPCR PAC1; SIP1, sphingosine 1-phosphate receptor 1; PDGF, platelet-derived growth factor; NGF, nerve growth factor; LPA1, lysophosphatidic acid receptor 1.*
to TLR4 receptors in both naïve and LPS-treated BMA cells. Conversely, TLR4 was found to be coimmunoprecipitated with MMP-9. Since both MMP-9 and NMBR form a complex with TLR4 receptors, we asked whether or not they are associated with each other. Coinmunoprecipitation experiments using cell lysates from RAW-Blue cells further demonstrated that NMBR 80 kDa isoform forms a complex with the active 88 kDa MMP9 isoform from naïve or LPS-stimulated cells. These data further validated that NMBR forms a complex with MMP-9 on the cell surface of naïve cells. The data in this report also showed that GPCR agonists such as bombesin, LPA, cholesterol, angiotensin-1 and -2, and bradykinin binding to their respective GPCR receptors induced Neu1 activity within 1 minute and that this activity was blocked by Gαi-sensitive pertussis toxin, neuraminidase inhibitor Tamiflu, broad-range MMP inhibitors galardin and piperazine, anti-Neu1 and anti-MMP-9 antibodies, and siRNA knockdown of MMP-9. The rapidity of the GPCR agonist-induced Neu1 activity suggests that glycosylated receptors like TLRs as well as RTK receptors form a functional GPCR-signaling complex.

Other reports have provided compelling evidence to show that the glycosylated platelet-derived growth factor-β receptor is tethered to an endogenous GPCR(s) and to a recombinant endothelial differentiation gene-1 protein (EDG1) in HEK-293 cells. EDG1 is also known as the S1P receptor 1 (S1PR1) which is encoded by the S1PRI gene. S1PRI encodes a GPCR that binds the lipid-signaling molecule sphingosine 1-phosphate (S1P). S1P and LPA are both bioactive lipid phosphates. Moughal et al reported that the constitutively active LPA, GPCR receptor enables Gβγ subunit proteins for use by the TrkA receptor. These Gβγ subunits were found to enhance the ability of NGF to promote TrkA signaling and subsequently regulate p42/p44 MAPK signaling pathway in PC12 rat pheochromocytoma cell line. LPA1 GPCR was found to coimmunoprecipitate with naïve and NGF-treated TrkA receptors in cell lysates, suggesting that LPA, GPCR forms a complex with TrkA. In addition, the findings suggest that NGF-induced stimulation of p42/p44 MAPK through the TrkA-LPA1 receptor complex appears to be dependent on Gβγ subunit proteins, while the activation of the p42/p44 MAPK cascade in response to LPA may involve predominantly Gαi subunit proteins. However, the LPA-induced stimulation of p42/p44MAPK was also found to be independent of the TrkA receptor in these studies.

Although GPCRs can exist as monomers, they can also form oligomeric structures composed of either homo- or heteromers, which may play important roles in modulating and fine-tuning GPCR function and GPCR-signaling specificity. There are several examples in the literature that show the importance of heteromerization in receptor functions. They suggest that alterations in GPCR cross talk can directly impact health and disease (Table 2). It follows that selective drugs targeting heteromers are of interest for pharmaceutical companies, and thus they constitute proof of heteromer existence in vivo. There are several review articles in the literature that focus on drug design targeting heteromers of GPCR, and they include (1) tools for drug discovery, (2) the structure of secreting family of GPCR and GPCR-signaling platforms, (3) drug-induced inactivation and reactivation to reveal GPCR dimer functions, (4) calcitonin-gene-related peptide-receptor antagonists and migraine, (5) pepducins (cell-penetrating lipidated peptides designed to target the intracellular loops of GPCR in disease models), (6) GPCR expression in tissues and cells for optimal drug targeting, use of GPCR structures for drug design, (8) drug design of GPCR ligands using physicochemicals, and (9) orphan GPCRs modulating the

<table>
<thead>
<tr>
<th>Disease category</th>
<th>Specific pathologies</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>Breast cancer</td>
<td>4,124–132</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Heart disease</td>
<td>126,128,133</td>
</tr>
<tr>
<td>Developmental</td>
<td>Precocious puberty</td>
<td>4,124,125,128,129</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Multiple sclerosis</td>
<td>134</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Obesity</td>
<td>125,127,128,135–137</td>
</tr>
<tr>
<td>Neurological</td>
<td>Alzheimer’s disease</td>
<td>4,125,126,128,138</td>
</tr>
<tr>
<td>Reproductive</td>
<td>Ovarian hyperstimulation syndrome</td>
<td>128</td>
</tr>
<tr>
<td>Vision</td>
<td>Fertility complications</td>
<td>124,125,128,136,137</td>
</tr>
</tbody>
</table>
function of well-defined drug targets such as GPCRs with identified ligands and neurotransmitter transporters through physical association with those molecules.10

In the context of GPCR oligomers when designing new drugs or alternative therapies against human disease, dysregulation of GPCR function is also associated with a growing number of human diseases.124 There are two mutational forms of GPCRs; the receptor loses the ability to bind agonist or signal ("loss of function" mutation) or the receptor is in an active state in the absence of agonist ("gain of function" mutation).125 A review article by Spiegel and Weinstein125 eloquently describes the mutations in the gene encoding the α subunit of the GPCRs. For example, there are mutations of the α subunit involved in the stimulation of adenyl cyclase causing the developmental abnormalities of bone, as well as hormone resistance (pseudohypoparathyroidism caused by loss-of-function mutations) and hormone hypersecretion (McCune–Albright syndrome caused by gain-of-function mutations). Loss- and gain-of-function mutations in genes encoding GPCRs have been identified as the cause of an increasing number of retinal, endocrine, metabolic, and developmental disorders.125

There are a number of constitutively active GPCRs, especially those that are tumorigenic in vitro and in animal models of human disease, that cause syndromes of hyperfunction and/or tumors in humans.124 A review article by Arvanitakis et al describes the spectrum of diseases caused by constitutively active GPCRs, including diseases involving infectious viral agents.124 To identify the GPCRs involved in human diseases, the review article by Schöneberg et al extensively describes the mutant GPCRs as a cause of human diseases.128 To date, over 600 inactivating and almost 100 activating mutations in GPCR have been identified, which are responsible for more than 30 different human diseases. The number of human disorders is expected to increase, given the fact that over 160 GPCRs have been targeted in mice.128

In addition to the diseases caused by loss-of-function mutations in GPCRs, dysfunction in basal activity can also cause human diseases.139 A review article by Tao139 summarizes several disease states caused by either constitutive activation (eg, rhodopsin mutations and retinitis pigmentosa or congenital stationary night blindness, TSH receptor mutations and hyperthyroidism, luteinizing hormone/choriogonadotropin receptor mutations and male-limited precocious puberty/Leydig cell adenoma, FSH receptor mutations and spontaneous ovarian hyperstimulation syndrome, parathyroid hormone receptor type 1 mutations, and Jansen’s metaphyseal chondrodysplasia) or loss of constitutive activity (eg, melanocortin-4 receptor mutations and obesity, growth hormone secretagogue receptor mutations and familial short stature/obesity). The evidence that the loss of constitutive activity in the mutant GPCR receptors can cause disease signifies the critical importance of the basal activity in the WT GPCRs in normal physiology.139

In conclusion, the identification of diseases caused by mutations in GPCRs should provide advances in novel forms of treatment for such diseases, including development of inverse agonists128 or pepducins129 to inhibit constitutively activated GPCRs, and methods to rescue function of misfolded or truncated GPCRs.107,116,137 These mutations may define critical GPCR structure–function relationships. Indeed, gene knockouts of GPCR in mice reveal many nonredundant, functionally important G proteins and GPCRs for which no human disease-causing mutations have yet been identified.125 Moreover, there are multiple orphan GPCRs for which the natural agonist is widely unknown. Given the large number of human GPCRs, estimated to be more than 800, additional examples of the pathogenic mechanisms and drug therapies are likely to be discovered in the future. In this respect, the future research focus might be directed at macrophage-mediated inflammation, as reviewed by Talukdar et al.135 Indeed, macrophage-mediated inflammation has been associated with many human diseases. They include rheumatoid arthritis, cancer, inflammatory bowel disease, cardiovascular disease, psoriasis, multiple sclerosis, and periodontitis. Furthermore, the expression of GPCRs differs in proinflammatory and anti-inflammatory macrophages.134 According to the novel GPCR-signaling platform (Figures 1 and 3) that is utilized by RTK and TLR receptors for downstream signaling and cellular function, we propose that there is a common GPCR tethered to these receptors.78 The findings propose a novel GPCR-signaling platform at the receptor level that has a common uncharacterized property with broader specificities than expected. Since several macrophage-expressed GPCRs have been identified and targeted with therapeutic intent in human diseases which involve infectious disease to cancer, studies about the key players involved in the GPCR agonist-induced transactivation of TLR receptors in the absence of TLR ligands, or reciprocally, TLR ligands potentiating GPCR-signaling to activate MMP-9 and Neu1 would radically redefine the current dogma(s) governing the mechanism of the cross talk between GPCR and TLR activation and cellular signaling. Targeting the molecular GPCR-signaling platform tethered to RTK or TLR receptors may provide
important pioneering approaches to disease-intervention strategies.

Acknowledgment
These studies were supported by a grant to MRS from the Natural Sciences and Engineering Research Council of Canada (NSERC). SA was the recipient of the RS McLaughlin Scholarship, the Ontario Graduate Scholarship, and now the Canadian Institutes of Health Research (CIHR) Doctoral Award: Frederick Banting and Charles Best Canada Graduate Scholarship. MH is the recipient of the NSERC Canada Graduate Scholarship (CGS-D3).

Disclosure
The authors report no conflicts of interest in this work.

References
57. Kopitz J, von RC, Burchert M, Cantz M, Gabius HJ. Galectin-1 is a
56. Papini N, Anastasia L, Tringali C, et al. The plasma membrane-
49. Sato K, Miyagi T. Involvement of an endogenous sialidase in skeletal
48. Miyagi T, Sagawa J, Konno K, Tsuiki S. Immunological discrimination
45. Duca L, Blanchevoye C, Cantarelli B, et al. The elastin receptor complex
44. Hinek A, Pshezhetsky AV, von IM, Starcher B. Lysosomal sialidase


